Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
2008
Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
2012
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Humanization of an anti-p185HER2 antibody for human cancer therapy.
1992
Development trends for monoclonal antibody cancer therapeutics
2007
Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains
1991 StandoutNobel
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
2008
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
1995 Standout
Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli
1989 StandoutNatureNobel
Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
2010
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody
1993
Role of Biochemical Mediators in Clinical Nutrition and Surgical Metabolism
1988
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
Man-made antibodies
1991 NatureNobel
Cancer immunotherapy: breaking the barriers to harvest the crop
2004 StandoutNobel
Production of IL‐10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma
1994
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
1990 Standout
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
2015
‘Sticky feet’-directed mutagenesis and its application to swapping antibody domains
1989 StandoutNobel
Reshaping human antibodies for therapy
1988 StandoutNatureNobel
IgG4-Related Disease
2012 Standout
Mammalian GPI proteins: sorting, membrane residence and functions
1997
Antibody framework residues affecting the conformation of the hypervariable loops
1992 StandoutNobel
Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo
1991
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
2001 Standout
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.
1992
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Combinatorial infection andin vivorecombination: a strategy for making large phage antibody repertoires
1993 StandoutNobel
Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding
2010
Building Antibodies from their Genes
1992 StandoutNobel
The Immune-Hypothalamic-Pituitary-Adrenal Axis*
1989
M-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
2009 Standout
Macrophages are critical effectors of antibody therapies for cancer
2015
Increased blood spermine levels decrease the cytotoxic activity of lymphokine-activated killer cells: a novel mechanism of cancer evasion
2006
Experimental membranous nephropathy redux
2005
Inflammation and cancer: back to Virchow?
2001 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Human IgG3 is decreased and IgG1, IgG2 and IgG4 are unchanged in molecular size by mild reduction and reoxidation without any major change in effector functions
1993
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
1990 Standout
Retroviral vectors displaying functional antibody fragments
1993 StandoutNobel
Phage antibodies: filamentous phage displaying antibody variable domains
1990 StandoutNatureNobel
Solution Conformation of Wild-Type and Mutant IgG3 and IgG4 Immunoglobulins Using Crystallohydrodynamics: Possible Implications for Complement Activation
2007
The Multichain Interleukin-2 Receptor: A Target for Immunotherapy
1992
De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease
2014
IgG4-related disease
2014 Standout
Clonal analysis of the cytolytic T-cell response to human tumors
1987
Humanized Antibodies as Potential Therapeutic Drugs
1998
Monoclonal-Antibody Therapy in Systemic Vasculitis
1990
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Phage libraries for generation of clinically useful antibodies
1994 StandoutNobel
Immunosuppressive activity of the retroviral envelope protein P 15E and its possible relationship to neoplasia
1984
A Personal History of the CAMPATH-1H Antibody
2002
Making antibody fragments using phage display libraries
1991 StandoutNatureNobel
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
1988
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
2011
Chimeric IgG4 PR3‐ANCA induces selective inflammatory responses from neutrophils through engagement of Fcγ receptors
2009
In-cell PCR from mRNA: amplifying and linking the rearranged immunoglobulin heavy and light chain V-genes within single cells
1992 StandoutNobel
IgG Subclasses and Allotypes: From Structure to Effector Functions
2014 Standout
Adapting antibodies for clinical use.
1992
Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers
2007 StandoutNobel
Generation of Lymphohematopoietic Cells from Embryonic Stem Cells in Culture
1994 StandoutScienceNobel
Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer
2007
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.
1993
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
1992 StandoutNobel
A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q
1994 StandoutNobel
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
1991 StandoutScience
2013
Synthetic Analogues of Glycosylphosphatidylinositol-Anchored Proteins and Their Behavior in Supported Lipid Bilayers
2007 StandoutNobel
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
2008
Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins.
1990
Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning.
1988
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
2001 StandoutNobel
Production of stable cytolytic T‐cell clones directed against autologous human melanoma
1987
Spermidine in health and disease
2018 StandoutScience
Potentiation of interleukin-2 activity by levamisole and imidazole
1987
In Vitro Antibodies: Strategies for Production and Application
1992
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
2008
Selective IgG subclass deficiency: quantification and clinical relevance
1990
Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
1997 StandoutNobel
"Diabodies": small bivalent and bispecific antibody fragments.
1993 StandoutNobel
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
1986 Nature
IgG4-Related Disease
2013
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
A chemical approach to unraveling the biological function of the glycosylphosphatidylinositol anchor
2007 StandoutNobel
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
A repertoire of monoclonal antibodies with human heavy chains from transgenic mice.
1989
The immunogenicity of chimeric antibodies.
1989 StandoutNobel
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
2014 Science
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
1985 Standout
Synthesis of Lipidated Green Fluorescent Protein and Its Incorporation in Supported Lipid Bilayers
2005 StandoutNobel
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
The In Vitro Generation of Effector Lymphocytes and Their Employment in Tumor Immunotherapy
1983
Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways
2011
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
1989 StandoutNobel
Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.
1992 StandoutNobel
Monoclonal Antibodies in Diagnosis and Therapy
1991 Science
Works of C Bindon being referenced
IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT‐MEDIATED LYSIS BY MONOCLONAL ANTIBODIES
1988
THERAPEUTIC POTENTIAL OF MONOCLONAL ANTIBODIES TO THE LEUKOCYTE-COMMON ANTIGEN
1985
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
1988
Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects
1983
Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2
1981
Inhibition of interleukin 2 production by factors released from tumor cells.
1983
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.
1987
A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha.
1989